Skip to main content

Advertisement

Table 1 Tumor and normal tissue distribution at 24 h post-injection of 111In- or 64Cu-DOTA-trastuzumab Fab

From: A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

  Percent injected dose/g a, b, c
Tissue 111 In-DOTA-trastuzumab
Fab
64 Cu-DOTA-trastuzumab
Fab
Blood 0.42 ± 0.08 1.40 ± 0.16
Heart 0.92 ± 0.06 2.42 ± 0.39
Lungs 0.80 ± 0.14 4.86 ± 0.57
Liver 3.13 ± 0.16 8.52 ± 0.81
Kidneys 62.85 ± 6.45 57.00 ± 7.09
Stomach 0.58 ± 0.05 3.41 ± 0.22
Intestines 0.61 ± 0.06 4.76 ± 0.41
Spleen 2.25 ± 0.13 5.00 ± 0.27
Muscle 0.78 ± 0.31 0.75 ± 0.06
Tumor 4.00 ± 0.91 5.01 ± 1.20
  1. 111In- or 64Cu-DOTA-trastuzumab Fab in athymic mice bearing subcutaneous MDA-MB-361 human breast cancer xenografts. aValues shown are mean ± SD (n = 4). bSignificantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for blood, heart, lungs, liver, stomach, intestines, and spleen (all P < 0.001). cNot significantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for kidneys, muscle, or tumor (P > 0.05).